Another phase-II single-arm study is currently recruiting participants with PD-1 relapsed/refractory melanoma to receive the anti-TIGIT domvanalimab (AB154) in combination with the anti-PD-1 zimberelimab (AB122) to assess the response of this combination (NCT05130177). This evidence concerns the gene PDCD1 and melanoma.